| Outcome Measures: |
Primary: Endothelial function, Impact of PIT on endothelial function before and one hour after the PIT initiation measured with the Vendys2 device, 1 hour | Secondary: Renal function, It will be assessed whether insulin resistance has improved or worsened over the course of the study. Measured laboratory parameters for renal function (GFR, creatinine, proteinurea), 13 weeks|nerve function, Sensory nerve function (pathtester, tuning fork). It will be assessed whether insulin resistance has improved or worsened over the course of the study., 13 weeks|Retinopathy, Retinopathy will be measured with the RetinaVue device. It will be assessed whether Retinopathy has improved or worsened over the course of the study., 13 weeks|HbA1c, metabolic control, 13 weeks|Insulin resistance, For assessment of insulin resistance glucose, retinol-binding protein 4 (RBP4), angiopoetin2, adiponectin, interleukin 6 (IL-6), hsCRP, glucagon, insulin, c-peptide, and intact Proinsulin will be measured. Finally, it is assessed whether insulin resistance has improved or worsened over the course of the study., 13 weeks|Diabetes treatment satisfaction questionnaire, Eight questions about the patient´s satisfaction with the diabetes treatment. Answer possibilities range form 1 (very good) to 10 (very bad), 13 weeks
|
| Locations: |
NYC Research, Inc., New York, New York, 10455, United States|Pfützner Science & Health Institute GmbH, Mainz, Rhineland-Palatinate, 55128, Germany
|
